Pharmacokinetics and pharmacodynamics of oseltamivir in neonates, infants and children

Infectious Disorders - Drug Targets

Volumn 13, Issue 1, 2013, Pages 6-14

  Standing, Joseph F ^a   Tsolia, Maria ^b   Lutsar, Irja ^c,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ATHENS   (Greece)

^c Institutes of Microbiology   (Estonia)

^d UNIVERSITY OF TARTU   (Estonia)

Author keywords

Children; Influenza; Neuraminidase inhibitors; Oseltamivir; Pharmacodynamics; Pharmacokinetics

Indexed keywords

OSELTAMIVIR; PLACEBO;

AREA UNDER THE CURVE; DOSE RESPONSE; DRUG HALF LIFE; HUMAN; IMMUNOCOMPROMISED PATIENT; INFLUENZA; OTITIS MEDIA; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW;

ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; NEURAMINIDASE; OSELTAMIVIR; VIRAL PROTEINS;

EID: 84878760745     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/18715265112129990003     Document Type: Review

References (59)

1. Cunney, R.J.; Bialachowski, A.; Thornley, D.; Smaill, F. M.; Pennie, R. A. An outbreak of influenza A in a neonatal intensive care unit. Infect. Control Hosp. Epidemiol., 2000, 21 (7), 449-454.
2. Fraaij, P.L.; van der Vries, E.; Beersma, M. F.; Riezebos-Brilman, A.; Niesters, H. G.; van der Eijk, A. A.; de Jong, M. D.; Reis Miranda, D.; Horrevorts, A. M.; Ridwan, B. U.; Wolfhagen, M. J.; Houmes, R. J.; van Dissel, J. T.; Fouchier, R. A.; Kroes, A. C.; Koopmans, M. P.; Osterhaus, A. D.; Boucher, C. A. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. J. Infect. Dis., 2011, 204 (5), 777-782.
3. Nair, H.; Brooks, W. A.; Katz, M.; Roca, A.; Berkley, J. A.; Madhi, S. A.; Simmerman, J. M.; Gordon, A.; Sato, M.; Howie, S.; Krishnan, A.; Ope, M.; Lindblade, K. A.; Carosone-Link, P.; Lucero, M.; Ochieng, W.; Kamimoto, L.; Dueger, E.; Bhat, N.; Vong, S.; Theodoratou, E.; Chittaganpitch, M.; Chimah, O.; Balmaseda, A.; Buchy, P.; Harris, E.; Evans, V.; Katayose, M.; Gaur, B.; O'Callaghan-Gordo, C.; Goswami, D.; Arvelo, W.; Venter, M.; Briese, T.; Tokarz, R.; Widdowson, M. A.; Mounts, A.W.; Breiman, R. F.; Feikin, D. R.; Klugman, K. P.; Olsen, S. J.; Gessner, B. D.; Wright, P. F.; Rudan, I.; Broor, S.; Simões, E. A.; Campbell, H. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet, 2011, 378 (9807), 1917-1930.
4. Neuzil, K. M.; Wright, P. F.; Mitchel, E. F. Jr.; Griffin, M. R. The burden of influenza illness in children with asthma and other chronic medical conditions. J. Pediatr., 2000; 137 (6), 856-864.
5. Poehling, K. A.; Edwards, K. M.; Weinberg, G. A.; Szilagyi, P.; Staat, M. A.; Iwane, M. K.; Bridges, C. B.; Grijalva, C. G.; Zhu, Y.; Bernstein, D. I.; Herrera, G.; Erdman, D.; Hall, C. B.; Seither, R.; Griffin, M. R.; New Vaccine Surveillance Network. The underrecognized burden of influenza in young children. N. Engl. J. Med., 2006, 355 (1), 31-40.
6. Effler, P. V. Every year is an influenza pandemic for children: can we stop them? Pediatrics, 2012, 130 (3), 554-556.
7. Fiore, A. E.; Fry, A.; Shay, D.; Gubareva, L.; Bresee, J. S.; Uyeki, T. M. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). M. M. W. R. Recomm. Rep., 2011, 60 (1), 1-24.
8. Jefferson, T.; Jones, M. A.; Doshi P.; Del Mar, C. B.; Heneghan, C. J.; Hama, R.; Thompson, M. J. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst. Rev., 2012, 1, CD008965.
9. Whitley, R. J.; Hayden, F. G.; Reisinger, K. S.; Young, N.; Dutkowski, R.; Ipe, D.; Mills, R. G.; Ward, P. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J., 2001, 20 (2), 127-133.
10. Neuzil, K. M.; Zhu, Y.; Griffin, M. R.; Edwards, K. M.; Thompson, J. M.; Tollefson, S. J.; Wright, P. F. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J. Infect. Dis., 2002; 185 (2):147-152.
11. Winther, B.; Block, S. L.; Reisinger, K.; Dutkowski, R. Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza. Int. J. Pediatr. Otorhinolaryngol., 2010, 74 (6), 684-688.
12. Farias, J. A.; Fernández, A.; Monteverde, E.; Vidal, N.; Arias, P.; Montes, M. J.; Rodríguez, G.; Allasia, M.; Ratto, M. E.; Jaén, R.; Meregalli, C.; Fiquepron, K.; Calvo, A. R.; Siaba, A.; Albano, L.; Poterala, R.; Neira, P.; Esteban, A. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med., 2010, 36 (6), 1015-1022.
13. Johnston, S. L.; Ferrero, F.; Garcia, M. L.; Dutkowski, R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr. Infect. Dis. J., 2005, 24 (3), 225-232.
14. Lee, J. Y.; Garnett, C. E.; Gobburu, J. V.; Bhattaram, V. A.; Brar, S.; Earp, J. C.; Jadhav, P. R.; Krudys, K.; Lesko, L. J.; Li, F.; Liu, J.; Madabushi, R.; Marathe, A.; Mehrotra, N.; Tornoe, C.; Wang, Y.; Zhu, H. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin. Pharmacokinet., 2011, 50 (10), 627-635.
15. Kimberlin, D. W.; Acosta, E. P.; Prichard, M. N.; Sánchez, P. J.; Ampofo, K.; Lang, D.; Ashouri, N.; Vanchiere, J. A.; Abzug, M. J.; Abughali, N.; Caserta, M. T., Englund, J. A.; Sood, S. K.; Spigarelli, M. G.; Bradley, J. S.; Lew, J.; Michaels, M. G.; Wan, W.; Cloud, G.; Jester, P.; Lakeman, F. D.; Whitley, R. J.; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. J. Infect. Dis., 2013, 207 (5), 709-720.
16. Ette, E. I.; Williams, P. J. Population pharmacokinetics I: background; concepts; and models. Ann. Pharmacother., 2004, 38 (10),1702-1706.
17. Ette, E. I.; Williams, P. J. Population pharmacokinetics II: estimation methods. Ann. Pharmacother., 2004, 38 (11),1907-1915.
18. Ette, E. I.; Williams, P. J.; Lane, J. R. Population pharmacokinetics III: design; analysis; and application of population pharmacokinetic Studies. Ann. Pharmacother., 2004, 38 (12), 2136-2144.
19. Anderson, B. J.; Holford, N. H. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet., 2009, 24 (1), 25-36.
20. Johansson, A. M.; Hill, N.; Perisoglou, M.; Whelan, J.; Karlsson, M. O.; Standing, J. F. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. Ther. Drug Monit., 2011, 33 (6), 711-718.
21. Danhof, M.; de Jongh, J.; De Lange, E. C.; Della Pasqua, O.; Ploeger, B. A.; Voskuyl, R. A. Mechanism-based pharmacokineticpharmacodynamic modeling: biophase distribution; receptor theory; and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 357-400.
22. Yang, D.; Pearce, R. E.; Wang, X.; Gaedigk, R.; Wan, Y. J.; Yan, B. Human carboxylesterases HCE1 and HCE2: ontogenic expression; inter-individual variability and differential hydrolysis of oseltamivir; aspirin; deltamethrin and permethrin. Biochem. Pharmacol., 2009, 77 (2), 238-247.
23. He, G.; Massarella, J.; Ward, P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet.,1999, 37 (6), 471-484.
24. Davies, B. E. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J. Antimicrob. Chemother., 2010, 65 (Suppl 2), ii5-ii10.
25. Meijer, W. J.; Bruinse, H. W.; van den Broek, M. P.; Kromdijk, W.; Wensing, A. M. Oseltamivir and its active metabolite cross the placenta at significant levels. Clin. Infect. Dis., 2012, 54 (11), 1676-1677.
26. Chairat, K.; Tarning, J.; White, N. J.; Lindegardh, N. Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. J. Clin. Pharmacol., 2013, 53 (2), 119-139.
27. Abdel-Rahman, S. M.; Newland, J. G.; Kearns, G. L. Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant. Paediatr. Drugs, 2011, 13 (1), 19-31.
28. Hayden, F. G.; Treanor, J. J.; Fritz, R. S.; Lobo, M.; Betts, R. F.; Miller, M.; Kinnersley, N.; Mills, R. G.; Ward, P.; Straus, S. E. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. J. A. M. A.,1999, 282 (13), 1240-1246.
29. Brennan, B. J.; Davies, B.; Cirrincione-Dall, G.; Morcos, P. N.; Beryozkina, A.; Chappey, C.; Aceves Baldo, P.; Lennon-Chrimes, S.; Rayner, C. R. Safety; tolerability; and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers. Antimicrob. Agents Chemother., 2012, 56 (9), 4729-4737.
30. Karie, S.; Launay-Vacher, V.; Janus, N.; Izzedine, H.; Deray, G. Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure. Nephrol. Dial. Transplant., 2006, 21 (12), 3606-3608.
31. Oxford, J. Oseltamivir in the management of influenza. Expert Opin. Pharmacother., 2005, 6 (14), 2493-2500.
32. McSharry, J. J.; Weng, Q.; Brown, A.; Kulawy, R.; Drusano, G. L. Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob. Agents Chemother., 2009, 53 (6), 2375-2381.
33. Canini, L.; Carrat, F. Population modeling of influenza A/H1N1 virus kinetics and symptom dynamics. J. Virol., 2011, 85 (6), 2764-2770.
34. Baccam, P.; Beauchemin, C.; Macken, C. A.; Hayden, F. G.; Perelson, A. S. Kinetics of influenza A virus infection in humans. J. Virol., 2006, 80 (15), 7590-7599.
35. Prague, M.; Commenges, D.; Drylewicz, J.; Thiebaut, R. Treatment monitoring of HIV-infected patients based on mechanistic models. Biometrics, 2012, 68 (3), 902-911.
36. Rihani, R.; Hayajneh, W.; Sultan, I.; Ghatasheh, L.; Abdel- Rahman, F.; Hussein, N.; Hussein, A.; Al-Zaben, A.; Sarhan, M.; Saad, M. Infections with the 2009 H1N1 influenza virus among hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant., 2011, 46 (11), 1430-1436.
37. Freitas, T. V.; Ono, G.; Correa, L.; Gomes, P. S.; Galante, N. Z.; Tedesco-Silva, H.; Camargo, L. F.; Medina-Pestana, J. O. Clinical manifestations and evolution of infection by influenza A (H1N1) in kidney transplant recipients. J. Bras. Nefrol., 2011, 33 (2), 136-141.
38. Tekgunduz, E.; Yuksel, M. K.; Erbay, C.; Aribas, B.; Ozdilekcan, C.; Arslan, H.; Kocubaba, S.; Demiriz, I.; Tetik, A.; Arda, K.; Altuntas, F. Pandemic 2009 H1N1 influenza in patients with hematopoietic stem cell transplantation and hematologic malignancy: single center experience. Oncology, 2010, 79 (5-6), 409-414.
39. Anton, A.; Lopez-Iglesias, A.A.; Tortola, T.; Ruiz-Camps, I.; Abrisqueta, P.; Llopart, L.; Marcos, M. A.; Martinez, M. J.; Tudo, G.; Bosch, F.; Pahissa, A.; de Anta, M. T.; Pumarola, T. Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors. Diagn. Microbiol. Infect. Dis., 2010, 68 (3), 214-219.
40. Ison, M. G.; Mishin, V. P.; Braciale, T. J.; Hayden, F. G.; Gubareva, L. V. Comparative activities of oseltamivir and A- 322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J. Infect. Dis., 2006, 193 (6), 765-772.
41. Holford, N. H. A size standard for pharmacokinetics. Clin. Pharmacokinet.,1996, 30 (5), 329-332.
42. Bjorkman, S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br. J. Clin. Pharmacol., 2005, 59 (6), 691-704.
43. Johnson, T. N.; Rostami-Hodjegan, A.; Tucker, G. T. Prediction of the clearance of eleven drugs and associated variability in neonates; infants and children. Clin. Pharmacokinet., 2006, 45 (9), 931-956.
44. Tod, M.; Jullien, V.; Pons, G. Facilitation of drug evaluation in children by population methods and modelling. Clin. Pharmacokinet., 2008, 47 (4), 231-243.
45. Rhodin, M. M.; Anderson, B. J.; Peters, A. M.; Coulthard, M. G.; Wilkins, B.; Cole, M.; Chatelut, E.; Grubb, A.; Veal, G. J.; Keir, M. J.; Holford, N. H. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr. Nephrol., 2009, 24 (1), 67-76.
46. Standing, J. F.; Nika, A.; Tsagris, V.; Kapetanakis, I.; Maltezou, H.C.; Kafetzis, D. A.; Tsolia, M. N. Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit. Antimicrob. Agents Chemother., 2012, 56 (7), 3833-3840.
47. Joint Formulary Committee. British National Formulary for Children (2012-2013); BMJ Group and Pharmaceutical Press: London, 2012.
48. Oo, C.; Barrett, J.; Hill, G.; Mann, J.; Dorr, A.; Dutkowski, R.; Ward, P. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr. Drugs, 2001, 3 (3), 229-236.
49. Oo, C.; Hill, G.; Dorr, A.; Liu, B.; Boellner, S.; Ward, P. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur. J. Clin. Pharmacol., 2003, 59 (5-6), 411-415.
50. Acosta, E. P.; Jester, P.; Gal, P.; Wimmer, J.; Wade, J.; Whitley, R. J.; Kimberlin, D. W. Oseltamivir dosing for influenza infection in premature neonates. J. Infect. Dis., 2010, 202 (4), 563-566.
51. McPherson, C.; Warner, B.; Hunstad, D. A.; Elward, A.; Acosta, E. P. Oseltamivir dosing in premature infants. J. Infect. Dis., 2012, 06 (6), 847-850.
52. Manolis, E.; Pons, G. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. Br. J. Clin. Pharmacol., 2009, 68 (4), 493-501.
53. Maltezou, H. C., Drakoulis, N.; Siahanidou, T.; Karalis, V.; Zervaki, E.; Dotsikas, Y.; Loukas, Y. L.; Theodoridou, M. Safety and pharmacokinetics of oseltamivir for prophylaxis of neonates exposed to influenza H1N1. Pediatr. Infect. Dis. J., 2012, 31 (5), 527-529.
54. Rayner, C. R.; Chanu, P.; Gieschke, R.; Boak, L. M.; Jonsson, E. N. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J. Clin. Pharmacol., 2008, 48 (8), 935-947.
55. Rath, B.; von Kleist, M.; Tief, F.; Karsch, K.; Tuerk, E.; Muehlhans, S.; Louis, F.; Skopnik, H.; Schweiger, B.; Duwe, S. Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with influenza A(H1N1) 2009 and influenza B viruses. Pediatr. Infect. Dis. J., 2012, 31 (9), 899-905.
56. Viberg, A.; Cars, O.; Karlsson, M.O.; Jonsson, S. Estimation of cefuroxime dosage using pharmacodynamic targets; MIC distributions; and minimization of a risk function. J. Clin. Pharmacol., 2008, 48 (11), 1270-1281.
57. Sheiner, L. B.; Melmon, K. L. The utility function of antihypertensive therapy. Ann. N.Y. Acad. Sci., 1978, 304, 112-127.
58. Li, C. C.; Wang, L.; Eng, H. L.; You, H. L.; Chang, L. S.; Tang, K. S.; Lin, Y. J.; Kuo, H. C.; Lee, I. K.; Liu, J. W.; Huang, E. Y.; Yang, K. D. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. Emerg. Infect. Dis., 2010, 16 (8), 1265-1272.
59. Sheiner, L.B. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther., 1997, 61 (3), 275-291.